In 1964, in the UCLA Department of Surgery, a zoologist named Paul Terasaki and his lab technician, John McClelland, needed blood for an experiment and had trouble getting enough of it. Unable to venipuncture each other, the two men pricked their own fingers instead. The shortage, Terasaki said afterward, was what produced the invention: a test that needed only a single microliter of serum, dropped into a plastic tray under a film of oil.
The tray answered one question: did a prospective transplant recipient's blood already contain antibodies that would attack a particular donor's kidney before a surgeon ever touched it. Mix the recipient's serum with the donor's white blood cells, add a dose of complement, and look under a microscope. If the donor's cells died, the recipient's immune system was already primed to destroy that kidney too. At a 1964 histocompatibility workshop at Duke University, Terasaki presented the first documented case of a human kidney transplant destroyed this way: attacked by antibodies the recipient's blood had been carrying all along.
By 1969, Terasaki and a colleague, Ramon Patel, had the numbers to show the pattern held at scale. Reporting on 413 kidney transplants performed at fifteen U.S. transplant centers in the New England Journal of Medicine, they found that 24 of the 30 patients transplanted despite a positive crossmatch lost the graft immediately, destroyed by the violent immune response doctors call hyperacute rejection. Immediate failure of that kind was rare among patients transplanted after a negative crossmatch. Transplant centers did not need persuading twice. In the years that followed, a positive crossmatch became close to an absolute reason to cancel a transplant, whatever the donor's blood type or how urgently the patient needed the kidney.
What made the crossmatch matter was not the biology, which surgeons already suspected. It was the shift in when the truth became available. Whether a recipient's blood carried antibodies primed to attack a particular donor's kidney had been a fact a surgeon could learn only by operating and watching what happened next; the crossmatch turned it into a fact a laboratory could establish before surgery, using a test built on blood two men had once needed to get from their own fingertips because there was none to spare.
A test like that succeeds without drama: a dye that marks the dead cells and leaves the living ones alone, counted one field at a time under a microscope. Terasaki had grown up needing that kind of discipline. As a child, he and his family were forced from Los Angeles into a wartime internment camp in Arizona, where they spent three years before rebuilding a life from almost nothing. What he built afterward, one microliter at a time, was a way of learning the truth about a kidney before a person's life was staked on getting it wrong.